Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00902434 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era

Start date: May 2009
Phase: N/A
Study type: Observational

This is an exploratory analysis that is investigating the pattern of care in patients over the age of 80 who were diagnosed with non-Hodgkin lymphoma (NHL). This study will look at the dose intensity and density implemented in this patient population to calculate whether patients received the full course of therapy, received less duration of treatment, or received lower doses of the drugs administered. Furthermore, the investigators would explore time to disease progression for these patients regardless of the treatment received and investigate whether patient outcomes differ based on the type of therapy or dose intensity/density given. This study is looking at retrospectively evaluating patients with NHL who are over the age of 80 at our institution between 2001-2007. It is anticipated that about 50 patients will be included in this study.

NCT ID: NCT00901615 Completed - Clinical trials for Mantle Cell Lymphoma

Lenalidomide and R-CHOP in B-cell Lymphoma

R2CHOP-1
Start date: January 6, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).

NCT ID: NCT00901147 Completed - Clinical trials for Angioimmunoblastic T-cell Lymphoma

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma after the failure of conventional chemotherapy.

NCT ID: NCT00901069 Completed - Lymphoma Clinical Trials

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year accrual period.

NCT ID: NCT00900484 Completed - Lymphoma Clinical Trials

SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Start date: February 1989
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how patients respond to treatment. PURPOSE: This laboratory study is collecting, analyzing, and storing tissue samples from patients with non-Hodgkin's lymphoma.

NCT ID: NCT00900406 Completed - Breast Cancer Clinical Trials

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Start date: January 2007
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of blood, urine, and tissue from patients undergoing a donor stem cell transplant to test in the laboratory may help the study of graft-versus-host disease in the future. PURPOSE: This research study is collecting and storing tissue and DNA samples from patients undergoing a donor stem cell transplant.

NCT ID: NCT00900250 Completed - Clinical trials for Refractory Childhood Hodgkin Lymphoma

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Start date: October 23, 2006
Phase:
Study type: Observational

This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.

NCT ID: NCT00899015 Completed - Lymphoma Clinical Trials

Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J

Start date: n/a
Phase: N/A
Study type: Observational

RATIONALE: Studying bone marrow and blood samples from patients with leukemia or lymphoma treated with arsenic trioxide may help doctors learn more about cancer. PURPOSE: This research study is assessing arsenic trioxide in young patients with recurrent or refractory leukemia or lymphoma who were treated on clinical trial NCI-00-C-0070J.

NCT ID: NCT00898963 Completed - Lymphoma Clinical Trials

Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496

Start date: April 18, 2007
Phase:
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.

NCT ID: NCT00898872 Completed - Lymphoma Clinical Trials

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Start date: March 1993
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of tissue from patients with non-Hodgkin lymphoma to study in the laboratory may help the study of cancer in the future. PURPOSE: This laboratory study is collecting and storing tissue samples from patients with relapsed or recurrent non-Hodgkin lymphoma after treatment on a Southwest Oncology Group (SWOG) clinical trial.